Suppr超能文献

急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.

作者信息

Goker Hakan, Ozdemir Evren, Uz Burak, Buyukasik Yahya, Turgut Mehmet, Serefhanoglu Songul, Aksu Salih, Sayinalp Nilgun, Haznedaroglu Ibrahim C, Tekin Fatma, Karacan Yasemin, Unal Sevilay, Eliacik Eylem, Isik Ayse, Ozcebe Osman I

机构信息

Division of Hematology, Department of Internal Medicine, Hacettepe University Medical School, Ankara, Turkey.

出版信息

Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.

Abstract

Due to the high transplant related morbidity and mortality (TRM), relatively younger acute leukemia patients that have a good performance status and no comorbidity are eligible for myeloablative conditioning (MAC) followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT). The outcomes of 84 consecutive adult patients with ALL (n=38) or AML (n=46) who underwent allo-HSCT from their HLA-identical siblings were evaluated retrospectively. The median age at transplantation was 34 (17-58 years) for the whole patient population. Of these, 24 patients received a MAC and 60 patients received a fludarabine-based reduced intensity conditioning regimen (RIC). After a median follow-up of 32 months (range, 1-119), for the entire group, the 3-year estimated overall survival (OS) was 57.5% and the disease-free survival (DFS) was 51.5%. The OS for ALL and AML patients were 53.9% vs 62.1%: and DFS were 50.5% and 53.4%, respectively. The 3-year estimated OS for RIC and MAC patients were 63.2% and 41.7%; and DFS were 57.1% and 34.7%, respectively. In ALL patients, conditioning regimens (RIC vs MAC) led to similar OS and DFS; however, in AML patients both OS (70.1% vs 21.4%) and DFS (59.3% vs 42.9%) were found to be higher in RIC patients compared to MAC recipients. Overall, the TRM at day 100 was 1.7% and has increased up to 5.1% at 1st year. In multivariate analysis, the diagnosis (p=0.03) and RIC regimen (p=0.027) were the prognostic variables for prolonged OS in all patients; and RIC regimen (p=0.031) was the only prognostic factor for prolonged OS in AML patients. The first complete remission (CR1) was correlated with a prolonged DFS as an independent variable for all patients (p=0.09). Eleven of the RIC patients (18.3%) and 6 of the MAC patients (25%) developed acute graft-versus-host disease (GvHD). Seventeen of the RIC patients (33.3%) and 4 of the MAC patients (16.7%) developed chronic GvHD. In conclusion, RIC conditioning regimens may provide a longer OS and DFS, especially in patients with AML who are in first CR, not eligible for MAC conditioning.

摘要

由于与移植相关的高发病率和死亡率(TRM),身体状况良好且无合并症的相对年轻的急性白血病患者有资格接受清髓性预处理(MAC),随后进行异基因造血干细胞移植(allo-HSCT)。回顾性评估了84例连续的成年急性淋巴细胞白血病(ALL,n = 38)或急性髓细胞白血病(AML,n = 46)患者,这些患者接受了来自其 HLA 相同同胞的 allo-HSCT。整个患者群体移植时的中位年龄为34岁(17 - 58岁)。其中,24例患者接受了MAC,60例患者接受了基于氟达拉滨的减低强度预处理方案(RIC)。中位随访32个月(范围1 - 119个月)后,整个组的3年估计总生存率(OS)为57.5%,无病生存率(DFS)为51.5%。ALL和AML患者的OS分别为53.9%和62.1%;DFS分别为50.5%和53.4%。RIC和MAC患者的3年估计OS分别为63.2%和41.7%;DFS分别为57.1%和34.7%。在ALL患者中,预处理方案(RIC与MAC)导致相似的OS和DFS;然而,在AML患者中,RIC患者的OS(70.1%对21.4%)和DFS(59.3%对42.9%)均高于接受MAC的患者。总体而言,100天时的TRM为1.7%,1年时升至5.1%。多因素分析中,诊断(p = 0.03)和RIC方案(p = 0.027)是所有患者OS延长的预后变量;RIC方案(p = 0.031)是AML患者OS延长的唯一预后因素。首次完全缓解(CR1)与所有患者DFS延长相关,作为独立变量(p = 0.09)。11例RIC患者(18.3%)和6例MAC患者(25%)发生了急性移植物抗宿主病(GvHD)。17例RIC患者(33.3%)和4例MAC患者(16.7%)发生了慢性GvHD。总之,RIC预处理方案可能提供更长的OS和DFS,尤其是对于处于首次CR且不符合MAC预处理条件的AML患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验